奥沙利铂联合替吉奥治疗对进展期食管癌患者生存时间的影响

Therapeutic efficacy of oxaliplatin combined with tigio in treating progressive esophageal cancer and its imapct on patients'survival

目的研究奥沙利铂联合替吉奥治疗进展期食管癌的效果及对患者生存时间的影响。方法84例进展期食管癌患者随机均分为观察组和对照组,对照组采用替吉奥联合顺铂干预,观察组采用替吉奥联合奥沙利铂干预,连续治疗4个周期;于治疗第1、第2及第4个周期时抽取患者肘静脉血5 mL,使用ELISA法检测血清糖类抗原199(CA199)、癌胚抗原(CEA)、血管内皮生长因子(VEGF)及糖类抗原125(CA125)水平,比较两组患者外周神经毒性反应、肝肾功能损害、胃肠道反应、血小板减少、白细胞减少等不良反应;比较两组患者的治疗效果;随访6个月后,比较两组患者总生存时间。结果观察组干预第1个周期、第2个周期及第4个周期时的CA125、CEA、CA199及VEGF改善情况均优于对照组,差异有统计学意义(P<0.05);观察组患者干预第1个周期、第2个周期及第4个周期后疾病改善率高于对照组,不良反应低于对照组,差异有统计学意义(P<0.05);6个月随访结果显示,观察组生存率高于对照组,差异有统计学意义(P<0.05)。结论奥沙利铂联合替吉奥治疗进展期食管癌患者可改善肿瘤标志物水平,提高用药安全性,延长生存时间。

Objective To investigate therapeutic efficacy of oxaliplatin combined with tigio in treating progressive esophageal cancer and its impact on patients'survival.Methods A total of 84 patients with progressive esophageal cancer were randomly divided into an observation group and a control group.Control group was given with tigio combined with cisplatin,while observation group received tigio combined with oxaliplatin.The treatment lasted for 4 consecutive cycles.At cycles 1,2,and 4 during treatment,5 mL of cubital venous blood was withdrawn from the patients.ELISA was applied to detect the levels of serum carbohydrate antigen 199(CA199),carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF),and carbohydrate antigen 125(CA125).Adverse reactions were compared between two groups,including peripheral neurotoxicity reactions,liver and kidney function damage,gastrointestinal reactions,thrombocytopenia and leukopenia.The therapeutic efficacy was compared between two groups.Follow-up lasted for 6 months.Overall survival time was compared betweem two groups of patients.Results The improvement of CA125,CEA,CA199,and VEGF in observation group was better than that in control group at cycles 1,2,and 4 after treatment(P<0.05).Disease improvement rate after 1 cycle,2 cycles,and 4 cycles in observation group was higher than that in control group,respectively(P<0.05).The 6-month follow-up result showed that the survival rate in observation group was higher than that in control group(P<0.05).Conclusion The combination of tigio and oxaliplatin in treating the patients with progressive esophageal cancer can improve tumor marker levels and medication safety,and prolong survival time.